达格列净对射血分数降低心力衰竭患者生物标志物、症状和功能状态的影响:DEFINE-HF试验
DEFINE-HF是一项多中心随机对照试验,纳入263例LVEF≤40%、NYHA II-III级的心衰患者,随机接受达格列净10mg每日一次或安慰剂治疗12周。结果显示,达格列净未显著降低平均NT-proBNP,但显著提高KCCQ或NT-proBNP改善的患者比例(61.5% vs 50.4%),且获益在无2型糖尿病患者中一致。
要点
- 达格列净12周未显著降低平均NT-proBNP水平。
- 达格列净显著提高KCCQ或NT-proBNP临床有意义改善的患者比例。
- 获益在伴或不伴2型糖尿病患者中一致。
核心结论
- 在射血分数降低的心衰患者中,达格列净治疗12周未影响平均NT-proBNP,但增加了心衰相关健康状态或利钠肽临床有意义改善的患者比例。
- 达格列净对临床有意义心衰指标的获益似乎延伸至无2型糖尿病的患者。
研究设计与样本
- DEFINE-HF为研究者发起、多中心、随机对照试验,纳入263例LVEF≤40%、NYHA II-III级、eGFR≥30 mL/min/1.73m2且利钠肽升高的心衰患者,随机接受达格列净10 mg每日一次或安慰剂治疗12周。
- 双主要终点为平均NT-proBNP和KCCQ总体 summary 评分改善≥5分或NT-proBNP降低≥20%的患者比例。
主要发现
- 达格列净组与安慰剂组6周和12周调整后平均NT-proBNP无显著差异(1133 pg/dL (95% CI 1036-1238) vs 1191 pg/dL (95% CI 1089-1304), P=0.43)。
- 达格列净组61.5%的患者达到KCCQ或NT-proBNP改善终点,安慰剂组为50.4%(调整OR 1.8, 95% CI 1.03-3.06, 名义P=0.039)。
- KCCQ改善≥5分的患者比例达格列净组为42.9%,安慰剂组为32.5%(调整OR 1.73, 95% CI 0.98-3.05)。
- NT-proBNP降低≥20%的患者比例达格列净组为44.0%,安慰剂组为29.4%(调整OR 1.9, 95% CI 1.1-3.3)。
- 结果在伴或不伴2型糖尿病患者及及其他预设亚组中一致(交互作用P值均无统计学意义)。
临床怎么用
- 对于射血分数降低的心衰患者,达格列净可考虑用于改善症状和健康状态,无论是否合并2型糖尿病。
- 达格列净对NT-proBNP的短期影响不显著,不应以NT-proBNP下降作为唯一疗效指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outcome trials in patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 inhibitors. However, few of these patients had HF, and those that did were not well-characterized. Thus, the effects of sodium-glucose co-transporter-2 inhibitors in patients with established HF with reduced ejection fraction, including those with and without type 2 diabetes mellitus, remain unknown. METHODS: DEFINE-HF (Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in Patients with HF with Reduced Ejection Fraction) was an investigator-initiated, multi-center, randomized controlled trial of HF patients with left ventricular ejection fraction ≤40%, New York Heart Association (NYHA) class II-III, estimated glomerular filtration rate ≥30 mL/min/1.73m2, and elevated natriuretic peptides. In total, 263 patients were randomized to dapagliflozin 10 mg daily or placebo for 12 weeks. Dual primary outcomes were (1) mean NT-proBNP (N-terminal pro b-type natriuretic peptide) and (2) proportion of patients with ≥5-point increase in HF disease-specific health status on the Kansas City Cardiomyopathy Questionnaire overall summary score, or a ≥20% decrease in NT-proBNP. RESULTS: Patient characteristics reflected stable, chronic HF with reduced ejection fraction with high use of optimal medical therapy. There was no significant difference in average 6- and 12-week adjusted NT-proBNP with dapagliflozin versus placebo (1133 pg/dL (95% CI 1036-1238) vs 1191 pg/dL (95% CI 1089-1304), P=0.43). For the second dual-primary outcome of a meaningful improvement in Kansas City Cardiomyopathy Questionnaire overall summary score or NT-proBNP, 61.5% of dapagliflozin-treated patients met this end point versus 50.4% with placebo (adjusted OR 1.8, 95% CI 1.03-3.06, nominal P=0.039). This was attributable to both higher proportions of patients with ≥5-point improvement in Kansas City Cardiomyopathy Questionnaire overall summary score (42.9 vs 32.5%, adjusted OR 1.73, 95% CI 0.98-3.05), and ≥20% reduction in NT-proBNP (44.0 vs 29.4%, adjusted OR 1.9, 95% CI 1.1-3.3) by 12 weeks. Results were consistent among patients with or without type 2 diabetes mellitus, and other prespecified subgroups (all P values for interaction=NS). CONCLUSIONS: In patients with heart failure and reduced ejection fraction, use of dapagliflozin over 12 weeks did not affect mean NT-proBNP but increased the proportion of patients experiencing clinically meaningful improvements in HF-related health status or natriuretic peptides. Benefits of dapagliflozin on clinically meaningful HF measures appear to extend to patients without type 2 diabetes mellitus. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02653482.
引用
- Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation. 2019. PMID: 31524498. doi:10.1161/CIRCULATIONAHA.119.042929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。